Sanofi-Aventis has launched its fast-acting insulin analogue Apidra (insulin glulisine) in Japan, for the management of prandial glycaemic levels in adults with diabetes mellitus.
The recombinant product is administered around meal times for the short-term control of blood sugar levels, and can be used...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?